• Cocrystal Pharma priced a USD 5 million private placement with OPKO Health, selling 5,474,053 common shares at USD 0.91 each.
• Deal used the Nasdaq Consolidated Bid Price on the closing day; no warrants or other derivative securities were included.
• OPKO Health increased its stake as Cocrystal targets Phase 1b norovirus topline data in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802081) on August 03, 2026, and is solely responsible for the information contained therein.